Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. (IVIVC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03553108
Recruitment Status : Active, not recruiting
First Posted : June 12, 2018
Last Update Posted : August 28, 2019
Sponsor:
Collaborators:
Iqvia Pty Ltd
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
This is a phase 1 open label, 4 treatment, 4 sequence and 4 period crossover study in subjects with solid tumours no longer responding to, or eligible for standard therapies, and for whom there are no additional standard therapies likely to benefit the subject.

Condition or disease Intervention/treatment Phase
Malignant Solid Tumor Drug: Olaparib Treatment A Drug: Olaparib Treatment B Drug: Olaparib Treatment C Drug: Olaparib Treatment D Phase 1

Detailed Description:

The study is an open-label, randomised, 4-period, 4-sequence crossover pharmacokinetic study designed to generate in vivo PK data from tablet variants with different size/geometry and dose, to correlate with their corresponding in vitro dissolution profiles. The duration of each dosing period is 7 days including the washout period. Subjects will be randomised to a treatment sequence, following a balanced Latin Squares design. Twelve subjects who meet inclusion/exclusion criteria and have provided informed consent will be randomly assigned to the treatment sequences: ABCD, BDAC, CADB, or DCBA.

On Day 1 of each period, subjects will receive a single dose of either Treatment A, B, C, or D, according to the randomisation schedule. Serial blood samples for determination of olaparib in plasma will be collected for up to 72 hours.

Cancer subjects with advanced solid tumours are required for this study, as pre-clinical toxicology data preclude the use of olaparib in healthy volunteers. The olaparib doses chosen will deliver exposure at or below that which has been previously demonstrated to be acceptable and tolerated in cancer subjects.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Protocol designed to evaluate one or more interventions for treating a disease, syndrome or condition
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomised, Open-label, 4-Period Crossover Study to Develop an In Vitro-In Vivo Correlation for Olaparib Tablets in Subjects With Solid Tumors
Actual Study Start Date : May 16, 2018
Actual Primary Completion Date : March 12, 2019
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Olaparib

Arm Intervention/treatment
Experimental: Olaparib Treatment Sequence ABCD

On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.

A - Olaparib Tablet 25 mg B - Olaparib Tablet 100 mg C - Olaparib Tablet 150 mg D - Olaparib Tablet 250 mg

Drug: Olaparib Treatment A
Olaparib Tablet 25 mg

Drug: Olaparib Treatment B
Olaparib Tablet 100 mg

Drug: Olaparib Treatment C
Olaparib Tablet 150 mg

Drug: Olaparib Treatment D
Olaparib Tablet 250 mg

Experimental: Olaparib Treatment Sequence BDAC

On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.

B - Olaparib Tablet 100 mg D - Olaparib Tablet 250 mg A - Olaparib Tablet 25 mg C - Olaparib Tablet 150 mg

Drug: Olaparib Treatment A
Olaparib Tablet 25 mg

Drug: Olaparib Treatment B
Olaparib Tablet 100 mg

Drug: Olaparib Treatment C
Olaparib Tablet 150 mg

Drug: Olaparib Treatment D
Olaparib Tablet 250 mg

Experimental: Olaparib Treatment Sequence CADB

On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.

C - Olaparib Tablet 150 mg A - Olaparib Tablet 25 mg D - Olaparib Tablet 250 mg B - Olaparib Tablet 100 mg

Drug: Olaparib Treatment A
Olaparib Tablet 25 mg

Drug: Olaparib Treatment B
Olaparib Tablet 100 mg

Drug: Olaparib Treatment C
Olaparib Tablet 150 mg

Drug: Olaparib Treatment D
Olaparib Tablet 250 mg

Experimental: Olaparib Treatment Sequence DCBA

On Day 1 of each period, patients will receive a single dose of either Tablet A, B, C, or D, according to the randomization schedule. Serial blood samples for determination of olaparib in plasma will be collected for 72 hours.

D - Olaparib Tablet 250 mg C - Olaparib Tablet 150 mg B - Olaparib Tablet 100 mg A - Olaparib Tablet 25 mg

Drug: Olaparib Treatment A
Olaparib Tablet 25 mg

Drug: Olaparib Treatment B
Olaparib Tablet 100 mg

Drug: Olaparib Treatment C
Olaparib Tablet 150 mg

Drug: Olaparib Treatment D
Olaparib Tablet 250 mg




Primary Outcome Measures :
  1. %PECmax [ Time Frame: 0 to 72 hours ]
    Percent prediction error for Cmax

  2. %PEAUC [ Time Frame: 0 to 72 hours ]
    Percent prediction error for AUC


Secondary Outcome Measures :
  1. Maximum plasma concentration (Cmax) obtained directly from the observed concentration versus time data. [ Time Frame: Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles. ]
    Evaluation of the PK parameters for the different Olaparib tablet variants.

  2. Time to maximum plasma concentration (tmax) obtained directly from the observed concentration versus time data. [ Time Frame: Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles. ]
    Evaluation of the PK parameters for the different Olaparib tablet variants.

  3. Area under the plasma concentration-time curve from zero to the time of the last measurable concentration (AUC(0-t)) calculated by linear up/log down trapezoidal summation. [ Time Frame: Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles. ]
    Evaluation of the PK parameters for the different Olaparib tablet variants.

  4. Area under the plasma concentration time curve from zero (pre-dose) extrapolated to infinity (AUC) [ Time Frame: Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles. ]
    Evaluation of the PK parameters for the different Olaparib tablet variants. calculated by linear up/log down trapezoidal summation and extrapolated to infinity by addition of the last quantifiable concentration divided by the terminal rate constant: AUC(0-t) + Clast/λz.

  5. Apparent plasma clearance (CL/F). [ Time Frame: Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles. ]
    Evaluation of the PK parameters for the different Olaparib tablet variants.

  6. Terminal half-life (t½). Visual assessment will be used to identify the terminal linear phase of the concentration-time profile. [ Time Frame: Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles. ]
    Evaluation of the PK parameters for the different Olaparib tablet variants.

  7. Apparent volume of distribution (Vz/F). [ Time Frame: Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles. ]
    Evaluation of the PK parameters for the different Olaparib tablet variants.

  8. Terminal rate constant (λz) estimated by log-linear least squares regression of the terminal part of the concentration-time curve. [ Time Frame: Blood samples will be taken at the following sampling times: Pre-dose, 30 min, 1 hr, 1.5 hr, 2 hr, 2.5 hr, 3 hr, 4 hr, 6 hr, 8 hr, 12 hr (Day 1), 24 hr (Day2), 48 hr (Day 3), and 72 hr (Day 4). After each dosing at each of the 4 treatment cycles. ]
    Evaluation of the PK parameters for the different Olaparib tablet variants.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of informed consent prior to any study specific procedures.
  2. Female or male subject, aged > 18 years.
  3. Histologically or, where appropriate, cytologically confirmed malignant solid tumour refractory or resistant to standard therapy for which no suitable effective standard therapy is available and in the opinion of the investigator might benefit from olaparib therapy.
  4. Subjects must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:

    • Haemoglobin ≥ 100 g/L with no blood transfusion in the past 28 days.
    • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L.
    • Platelet count ≥ 100 x 109/L.
    • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN).
    • Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5x ULN.
    • Subjects must have creatinine clearance estimated of ≥51 mL/min using the Cockcroft-Gault equation or based on a 24 hour urine test:

    Estimated creatinine clearance =[(140-age [years]) x weight (kg) x 1.2] (x F)a serum creatinine (μmol/L) a where F=0.85 for females and F=1 for males

  5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  6. Subjects must have a life expectancy ≥ 16 weeks.
  7. Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1.

8 Male subjects must use a condom during treatment and for 3 months after the last dose of olaparib when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male subjects should also use a highly effective form of contraception if they are of childbearing potential.

9 Subjects must have normal GI tract anatomy and function (see exclusion criteria for specifics).

10 Subjects is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.

Exclusion Criteria:

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  2. Previous randomisation in the present study.
  3. Participation in another clinical study with an investigational product during the last 1 month.
  4. Any previous treatment with a PARP inhibitor, including olaparib.
  5. Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation > 500 ms, electrolyte disturbances, etc.) or subjects with congenital long QT syndrome.
  6. Subjects receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within 3 weeks prior to study treatment.
  7. Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.
  8. Concomitant use of known strong (e.g. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
  9. Persistent toxicities (Common Terminology Criteria for Adverse Event (CTCAE) > grade 2) caused by previous cancer therapy, excluding alopecia.
  10. Subjects with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML.
  11. Subjects with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. The subject can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Subjects with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days
  12. Major surgery within 2 weeks of starting study treatment and subjects must have recovered from any effects of any major surgery.
  13. Subjects considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent.
  14. Subjects unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with absorption of the study medication including surgery on the upper GI tract and small bowel, malabsorptive disorders, inflammatory bowel disease, GI motility disorders, chronic diarrhea (more than 3 loose bowel movements per day) chronic constipation (no bowel movement for more than two days), recent (in last week) vomiting.
  15. Pregnant or breastfeeding women.
  16. Immunocompromised subjects, e.g., subjects who are known to be serologically positive for human immunodeficiency virus (HIV).
  17. Subjects with a known hypersensitivity to olaparib or any of the excipients of the product.
  18. Subjects with known active hepatitis (i.e. Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.
  19. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03553108


Locations
Layout table for location information
Belgium
Research Site
Leuven, Belgium, 3000
Research Site
Liège, Belgium, 4000
Research Site
Wilrijk, Belgium, 2610
Sponsors and Collaborators
AstraZeneca
Iqvia Pty Ltd
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Kevin Punie Universitaire Aiekenhuizen Leuven
Principal Investigator: Luc Dirix GZA Ziekenhuizen
Principal Investigator: Guy Jerusalem Centre Hospitalier Universitaire de Liège

Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT03553108     History of Changes
Other Study ID Numbers: D0816C00024
First Posted: June 12, 2018    Key Record Dates
Last Update Posted: August 28, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AstraZeneca:
Solid Tumor
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Olaparib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents